2021 ESC Clinical Practice Recommendations on the use of SGLT-2 Inhibitors in Heart Failure: An Assessment of their Impact

Published: 07 September 2021

  • Views:

    Views Icon 916
  • Likes:

    Heart Icon 2

Overview

Full programme

  • Views:

    Views Icon 916
  • Likes:

    Heart Icon 2

Overview

In this first roundtable of the series, we consider SGLT-2 inhibitors in light of the new ESC 2021 heart failure guidance and gauge expert opinion on the immediate and future impact on the treatment of HFrEF.
 

Prof Andrew Coats is joined by Prof Lars Lund, Dr Michele Senni and Prof Ewa Anita Jankowska to give a detailed assessment of the updates, distilling all you need to know in a series of four short videos. The dialogue provides expert insight on how the new guidelines have been updated since 2016, the clinical evidence underpinning the latest recommendations on SGLT-2 inhibitors, and considers how the cardiology community can successfully adopt these agents into everyday practice.  

Supported by the Boehringer Ingelheim & Lilly Alliance

Series overview

Part 1

Care gaps in heart failure guidelines: Where were we?

1 session

  • Care gaps in heart failure guidelines: Where were we?

    Watch now

Part 2

New evidence on SGLT-2 inhibitors in HF

1 session

  • New evidence on SGLT-2 inhibitors in HF

    Watch now

Part 3

2021 ESC updates: Where are we now?

1 session

  • 2021 ESC updates: Where are we now?

    Watch now

Part 4

Future perspectives and controversies 

1 session

  • Future perspectives and controversies 

    Watch now

Faculty biographies